Enantiomeric LC separation of valsartan on amylose based stationary phase

Pharmazie

Volumn 64, Issue 8, 2009, Pages 495-498

  Rane, V ^a   Patil, K ^a   Shinde, Devanand ^a  

^a DR BABASAHEB AMBEDKAR MARATHWADA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPANOL; AMYLOSE; HEXANE; TRIFLUOROACETIC ACID; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; TETRAZOLE DERIVATIVE; VALINE;

ARTICLE; CALIBRATION; DRUG DETERMINATION; DRUG FORMULATION; ENANTIOMER; LIQUID CHROMATOGRAPHY; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; REGRESSION ANALYSIS; REPRODUCIBILITY; STEREOISOMERISM; TABLET;

AMYLOSE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INDICATORS AND REAGENTS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; TABLETS; TETRAZOLES; VALINE;

EID: 70349758755     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9071     Document Type: Article

References (13)

1. Buhlmayer P, Criscione L, De Gasparo M, Whitebread S, Schmidlin T, Wood L (1994) Valsartan a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series. J Bioorg Med Chem Lett 4: 29-34.
2. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F (1996) Valsartan, comparative studies have the efficacy and Safety against amoldipine. Clin Pharmacol Ther 60: 341-346.
3. Francotte E, Davatz A, Richert P (1996) Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valasartan and of the tosylate of valinebenzyl ester. J Chromatogr B Biomed Appl. 686: 77-83.
4. ICH draft Guidelines on Validation of Analytical Procedures; Definitions and Terminology, Federal Register, 60, IFPMA, Switzerland, 1995, p. 11260
5. Lars K, Torp-Pederson C (2005) Valsartan: the past, present and future. J Future Cardiology 1: 591-598.
6. Macek J, Klima J, Ptacek P (2006) Rapid determination of Valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B 832: 169-172.
7. Mussoni L (2001) Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Hypertension 37: 961-966, 1050.
8. Nie J, Zhang M, Fan Y, Wen Y, Xiang B, Feng YQ (2005) Biocompatible in-tube solid-phase micro extraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine. J Chromatogr B 828: 62-69.
9. Satana E, Altinay S, Goger NG, Ozkan SA, Senturk Z (2001) Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrometry and LC. J Pharm Biomed Anal 25: 1009-1013.
10. Sironi L, Calvio AM, Arnaboldi L, Corsini A, Parolai A, de Gasparo M, Tremoli E, Mussoni L (2001) Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Hypertension 37: 961-966, 1050.
11. Tatar S, Saglik S (2002) Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J Pharm Biomed Anal 30: 371-375.
12. Okamoto Y, Kaida Y (1994) Resolution by high-performance liquid chromatography using polysaccharide carbamates and benzoates as chiral stationary phases. J Chromatogr A 666: 403-419.
13. Okamoto Y, Yashima E (1998) Polysaccharide derivatives for chromatographic separation of enantiomers. Angew Chem Int Ed 37: 1020-1043.